Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Dose-Ranging Study to Evaluate the Pharmacokinetics and Initial Safety of Subcutaneous and Intramuscular Natalizumab in Subjects With Multiple Sclerosis

NCT00559702 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT00559702
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00559702 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Dose-Ranging Study to Evaluate the Pharmacokinetics and Initial Safety of Subcutaneous and Intramuscular Natalizumab in Subjects With Multiple Sclerosis
Lead sponsor
Biogen
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2007
Completion date
November 30, 2011
Enrollment
76 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis